The effects of sarilumab as monotherapy and in combination with non-methotrexate disease-modifying anti-rheumatic drugs on unacceptable pain in patients with rheumatoid arthritis: A post-hoc analysis of the HARUKA phase 3 study.

Autor: Tanaka Y; The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Fukuoka, Japan., Takahashi T; Medical Affairs Department, Asahi Kasei Pharma Corporation, Tokyo, Japan., van Hoogstraten H; Global Medical Affairs, Sanofi US, Bridgewater, NJ, United States., Kato N; Medical Affairs Department, Asahi Kasei Pharma Corporation, Tokyo, Japan., Kameda H; Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Toho University, Tokyo, Japan.

Publikováno v: Modern rheumatology [Mod Rheumatol] 2024 Dec 25; Vol. 35 (1), pp. 27-33.

Real-world Effectiveness of Sarilumab in RA: Results from the Open-label, Prospective, Single-arm Observational PROFILE Study.

Autor: Kivitz A; Altoona Centre for Clinical Research, 175 Meadowbrook Lane, Duncansville, PA, 16635-8445, USA. ajkivitz@yahoo.com., Gottenberg JE; Department of Rheumatology, Hôpitaux de Hautepierre, Strasbourg, France., Bergman M; Department of Medicine, Drexel University College of Medicine, Philadelphia, PA, USA., Qiu C; Sanofi, Bridgewater, NJ, USA., van Hoogstraten H; Sanofi, Bridgewater, NJ, USA., de Nijs R; Department of Rheumatology, Elkerliek Hospital, Helmond, The Netherlands., Bessette L; Department of Medicine, Université Laval, Québec, Québec, Canada.

Publikováno v: Rheumatology and therapy [Rheumatol Ther] 2024 Dec; Vol. 11 (6), pp. 1533-1550. Date of Electronic Publication: 2024 Sep 16.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Long-term safety and efficacy of sarilumab with or without background csDMARDs in rheumatoid arthritis.

Autor: Burmester GR; Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin, Berlin, Germany., Strand V; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, CA, USA., Kivitz AJ; Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, USA., Hu CC; Sanofi, Bridgewater, NJ, USA., Wang S; Sanofi, Bridgewater, NJ, USA., van Hoogstraten H; Sanofi, Bridgewater, NJ, USA., Klier GL; Sanofi, Bridgewater, NJ, USA., Fleischmann R; University of Texas Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX, USA.

Publikováno v: Rheumatology (Oxford, England) [Rheumatology (Oxford)] 2023 Oct 03; Vol. 62 (10), pp. 3268-3279.

Disproportionate articular pain is a frequent phenomenon in rheumatoid arthritis and responds to treatment with sarilumab.

Autor: Choy E; CREATE Centre, Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK., Bykerk V; Inflammatory Arthritis Centre, Hospital for Special Surgery, New York, NY, USA., Lee YC; Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA., van Hoogstraten H; Neurology and Immunology, Sanofi, Bridgewater, NJ, USA., Ford K; Medical Affairs Immunology and Inflammation-Rheumatology, Rare Inflammatory Disorders, Sanofi, Bridgewater, NJ, USA., Praestgaard A; Biostatistics, Immunology, Sanofi, Cambridge, MA, USA., Perrot S; Pain Center, Cochin Hospital, Paris University, Paris, France., Pope J; Division of Rheumatology, Schulich School of Medicine, University of Western Ontario, St. Joseph's Health Care, London, ON, Canada., Sebba A; Department of Rheumatology, University of South Florida, Tampa, FL, USA.

Publikováno v: Rheumatology (Oxford, England) [Rheumatology (Oxford)] 2023 Jul 05; Vol. 62 (7), pp. 2386-2393.